

OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-19 18:13:48

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Avian mycoplasmosis (Mycoplasma gallisepticum)
Address of laboratory:	San José de las Lajas Provincia Mayabeque CUBA
Tel.:	+53-47 86.33.14 ext.
Fax:	+53-47 86.38.97
E-mail address:	elobo@censa.edu.cu
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	DrC. Evelyn Lobo Rivero Jefe de MYCOLAB
Name (including Title and Position) of OIE Reference Expert:	DrC. Evelin Lobo Rivero Jefe de MYCOLAB
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
no	no	no	no
Direct diagnostic tests			
PCR	si	si	no
Cultivo microbiológico	si	si	no

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
MALAYSIA	sobre diagnostico de Mycoplasma basado en aislamiento, PCR y seroaglutinación rapida en placa (SAR)	intercambio de información, procedimientos y protocolos
FINLAND	información sobre alcance y posibilidades fiables de utilizar antígenos SAR y ELISA para otras especies de aves que no sean gallinas y pavos	intercambio de información, procedimientos y protocolos
ECUADOR	sobre estudios de genes de resistencia en <i>Mycoplasma gallisepticum</i>	intercambio de información, procedimientos y protocolos

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Se investigó la presencia de MG en 22 parvadas comerciales de pollos de engorde ubicadas en diferentes zonas de la provincia de Manabí, Ecuador. El muestreo se realizó a partir de un total de 330 hisopos traqueales pertenecientes a la selección de 15 pollos/manada con edades comprendidas entre las cinco y las seis semanas. A las muestras que fueron confirmadas como positivas a MG para el gen <i>mgc2</i> se les determinó la presencia de regiones determinantes de la resistencia a las quinolonas (QRDRs) a través de la amplificación de los genes <i>parC</i> y <i>gyrA</i> . MYCOLAB procesó los datos obtenidos de este estudio

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
A partir de los resultados obtenidos fue elaborado un artículo y enviado para su divulgación al Spanish Journal Agrícola

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1

Mutations in the quinolone resistance-determining region (QRDR) of the *gyrA* and *parC* genes in *Mycoplasma gallisepticum* positive samples from chickens in Manabí-Ecuador province. Enviado al Spanish Journal Agrícola, actualmente en revisión

b) International conferences: 0

c) National conferences: 1

Actualización de la micoplasmosis aviar. Tendencia en el estudio de la resistencia antimicrobiana. Presentado en el taller nacional sobre Resistencia Antimicrobiana (RAM) efectuado en marzo del 2021, Hotel Tulipan, LA Habana Cuba

d) Other:

(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
NC:ISO/IEC 17025, 2017	_DSC0048.JPG

16. Is your quality management system accredited?

No

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories

designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

Durante el 2021, las actividades de MYCOLAB se han visto limitadas debido a la pandemia COVID-19 tanto en lo referido al intercambio de material biológico como de recursos humanos (como parte de la formación y capacitación). El país ha presentado serias restricciones del movimiento tanto de personal como de biológico lo cual también incidieron en el número de muestras que trabajó el laboratorio.

La participación en estudios interlaboratorios nacionales no es aplicable en estos momentos pues solo se

mantiene activo MYCOLAB como laboratorio para el diagnóstico de MG y MS a nivel nacional

Las actividades relacionadas con la reacreditación estuvieron deternidas por parte del Organo Nacional de Acreditación de la República de Cuba (ONARC) producto a la pandemia